Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Direct Integrative Care  |  Telemedicine Practice

Introduction

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, affects an estimated 80,000 children and adolescents in the United States alone. Managing pediatric IBD presents unique challenges: conventional biologics and immunosuppressants carry significant risks of infection, growth impairment, and long-term immunological consequences in a developing immune system. Clinicians and families are increasingly seeking adjunctive, lower-risk therapeutic options that may reduce disease burden while preserving quality of life.

Low-dose naltrexone (LDN) has emerged as a promising integrative option in this context. Originally approved by the FDA at 50 mg/day for opioid and alcohol use disorder, naltrexone at doses between 1.5 and 4.5 mg (or weight-based equivalents in children) exerts fundamentally different pharmacologic effects—primarily through transient opioid receptor blockade and antagonism of Toll-like receptor 4 (TLR4)—resulting in immune modulation rather than opioid antagonism. In pediatric IBD, a small but important body of evidence now supports both the safety and preliminary efficacy of LDN in moderate-to-severe Crohn’s disease.

This article reviews the key clinical evidence, mechanistic rationale, practical dosing protocols, monitoring parameters, and counseling considerations for the use of LDN in pediatric IBD.

Mechanisms of Action Relevant to Pediatric IBD

LDN’s therapeutic effects arise from pharmacologic mechanisms that are distinct from those of full-dose naltrexone. At low doses, transient blockade of opioid receptors triggers a compensatory upregulation of endogenous opioid production—including beta-endorphin and met-enkephalin—which plays a significant role in mucosal immune regulation, gut motility, and intestinal barrier integrity.

Equally important is LDN’s action at TLR4 on microglia and macrophages. By antagonizing TLR4 signaling, LDN dampens the production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-12, which are central to the pathophysiology of Crohn’s disease. This mechanism is particularly relevant in the intestinal mucosa, where macrophage-driven inflammation sustains mucosal injury and barrier dysfunction.

In the context of pediatric disease, these mechanisms may carry special significance. Children’s mucosal immune systems are less adapted to chronic inflammatory signaling, and structural complications such as bowel fibrosis and stricturing—common in longstanding adult Crohn’s—are less entrenched early in the disease course. This may create a window of particular responsiveness to immune-modulating interventions like LDN.

Clinical Evidence in Pediatric IBD

The Penn State Pilot RCT (Smith et al., 2013)

The most pivotal pediatric study to date is a randomized, double-blind pilot trial conducted at Penn State by Smith and colleagues, published in the Journal of Clinical Gastroenterology in 2013. This landmark study enrolled 14 children (mean age 12.3 years; range 8–17) with moderate-to-severe Crohn’s disease.

The trial design consisted of:

• An 8-week randomized, double-blind phase comparing LDN to placebo
• Followed by an 8-week open-label extension in which all participants received LDN

The dosing protocol was weight-based: 0.1 mg/kg orally once nightly at bedtime, not to exceed 4.5 mg per day. Identical placebo capsules or suspension were used to maintain blinding.

Primary and secondary outcomes included the Pediatric Crohn’s Disease Activity Index (PCDAI), plasma inflammatory markers (CRP and ESR), weight, and the validated pediatric quality-of-life instrument IMPACT III.

Key Findings

Efficacy: PCDAI scores declined significantly in the LDN group compared to placebo during the blinded phase. In the combined blinded and open-label data, approximately 25% of LDN-treated children achieved clinical remission (PCDAI < 10), compared to 0% in the placebo group. Clinical response rates (defined as a meaningful reduction in PCDAI) were substantially higher with LDN.

Safety and Tolerability: LDN was well tolerated across the 16-week combined treatment period. No serious adverse events were observed. Mild, transient side effects—primarily vivid dreams and brief sleep disturbance in the first week or two—were reported in a subset of children but resolved spontaneously without dose adjustment.

Quality of Life: IMPACT III scores did not worsen and showed improvement trends in domains of wellbeing and psychosocial function, suggesting LDN may carry benefits beyond biochemical disease control in children.

Norwegian Registry Data

A quasi-experimental registry study from Norway (Lie et al., J Crohns Colitis, 2018) examined adults and older adolescents with IBD who maintained LDN use. Persistent LDN users had significantly reduced dispensing of intestinal anti-inflammatory agents, corticosteroids, and other immunosuppressants compared to non-users, suggesting a steroid- and immunosuppressant-sparing effect that may be clinically meaningful in a pediatric population where corticosteroid exposure carries particular risks to growth and bone density.

Supportive Pediatric Tolerability Data

Additional pediatric data from non-IBD contexts inform the broader safety profile of LDN in children:

• Autism and self-injurious behavior studies have used LDN at 0.5–2 mg/kg/day without serious adverse events
• Retrospective cohorts in pediatric PANS/PANDAS, complex regional pain syndrome (CRPS), and fibromyalgia-like syndromes demonstrate improved pain and disability scores at doses of 0.1–0.3 mg/kg or 1.5–4.5 mg nightly
• Across these pediatric contexts, the most consistently reported side effects are transient sleep changes, which typically resolve within 1–2 weeks

Practical Dosing in Pediatric IBD

All pediatric LDN use in IBD is currently off-label. The dosing guidance below reflects the available trial data supplemented by expert clinical opinion.

Formulation note: Commercial naltrexone tablets are available only at 50 mg. Achieving accurate low pediatric doses requires compounded preparations—either oral capsules or, for younger children or those with swallowing difficulties, oral suspension. A compounding pharmacist experienced with LDN preparations is essential to accurate dosing.

Timing: Administration at bedtime is standard, as endogenous opioid surges during sleep hours are theorized to amplify the compensatory endorphin response. Bedtime dosing also helps confine any initial sleep-related side effects to nocturnal hours.

Titration: For children under 40 kg, a slower titration starting at 0.1 mg and incrementally increasing over several weeks helps minimize sleep disruption. For children ≥40 kg managed similarly to adults, beginning at 1 mg and increasing by 0.5–1 mg every 1–2 weeks up to 3–4.5 mg is a reasonable approach, though this is based on expert opinion rather than IBD-specific trial data.

Monitoring Parameters

Given the off-label status and the developing physiology of pediatric patients, systematic monitoring is essential:

• Baseline and periodic liver function tests (LFTs) — naltrexone at full dose has hepatotoxic potential at high doses; monitoring is prudent even at low doses
• Growth parameters — height, weight, BMI at each visit
• Inflammatory markers — CRP, ESR, and fecal calprotectin where accessible
• Disease activity scoring — PCDAI at baseline, 8 weeks, and 16 weeks minimum
• Sleep quality and neurologic symptoms — including parent/child report of dream frequency, mood changes, and behavior
• Concurrent medication review — LDN should not be co-administered with full-dose opioids or opioid-containing medications, which it may precipitously block

Positioning LDN in the Pediatric IBD Treatment Algorithm

Based on current evidence, LDN is best positioned as an experimental adjunct in moderate-to-severe pediatric Crohn’s disease—not a replacement for guideline-directed standard therapy. Its most appropriate use contexts include:

• Children with active Crohn’s disease who have had inadequate response or intolerance to conventional therapy
• As a steroid-sparing adjunct to reduce cumulative corticosteroid exposure
• In families who wish to minimize immunosuppressive burden while maintaining disease control
• As a low-toxicity bridge therapy in patients awaiting initiation of biologic therapy

There are currently no adequate pediatric data for LDN in ulcerative colitis, and the evidence base overall remains preliminary. Larger, multicenter randomized controlled trials are needed to establish efficacy endpoints, optimal dosing ranges, and long-term safety in pediatric IBD before LDN can be considered standard of care.

Informed Consent and Family Counseling

Given the off-label status of LDN in pediatric IBD, thorough informed consent is ethically and legally essential. Key counseling points include:

• LDN is not FDA-approved for IBD or for pediatric use at low doses
• The existing evidence is preliminary, based primarily on one small RCT with 14 children
• Short-term safety data (up to 16 weeks) are reassuring; long-term pediatric safety data in IBD are unavailable
• LDN should not replace or delay guideline-recommended therapies where indicated
• Families should be counseled on the importance of ongoing monitoring and the need to report new symptoms promptly
• Compounding costs are typically out-of-pocket, as LDN is rarely covered by insurance at these doses

Conclusion

Low-dose naltrexone represents a compelling, mechanistically grounded, and thus far safely tolerated adjunctive option for moderate-to-severe pediatric Crohn’s disease. The Penn State pilot RCT remains the cornerstone of pediatric evidence, demonstrating meaningful reductions in disease activity, clinical remission in a subset of children, and a favorable short-term safety profile at a weight-based dose of 0.1 mg/kg per day (maximum 4.5 mg nightly).

For integrative clinicians managing children with IBD, LDN offers a low-toxicity, immune-modulating option that merits serious consideration—particularly in the context of a comprehensive, individualized treatment plan. As the evidence base continues to mature, LDN may find a more formalized role in pediatric IBD care. Until then, thoughtful patient selection, compounding accuracy, systematic monitoring, and transparent family counseling remain the pillars of responsible clinical use.

References

1. Smith BA, Caring CE, Homan A, et al. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. J Clin Gastroenterol. 2013;47(4):339-345. Available at: https://pure.psu.edu/en/publications/safety-and-tolerability-of-low-dose-naltrexone-therapy-in-childre/
2. ClinicalTrials.gov. The Efficacy of Low Dose Naltrexone Therapy in Children With Moderate to Severe Crohn's Disease. NCT00715117. https://clinicaltrials.gov/study/NCT00715117
3. Svendsen K, Borchgrevink PC, Fredheim OMS, et al. Low-dose naltrexone for the induction of remission in patients with inflammatory bowel disease. Pharmacol Res Perspect. 2022;10:e00948. PMID: 35277974. https://pmc.ncbi.nlm.nih.gov/articles/PMC8996009/
4. Lie MRKL, van der Giessen J, Fuhler GM, et al. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med. 2018;16(1):55. https://academic.oup.com/ecco-jcc/article/12/6/677/4827597
5. Parker CE, Nguyen TM, Segal D, et al. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2018;4(4):CD010410.
6. LDN Research Trust. LDN and Crohn's Disease: Clinical Evidence Summary. https://ldnresearchtrust.org/content/ldn-and-crohns-disease
7. Fakhoury M, Fakhoury HH, Imber BS. Developmental Considerations for the Use of Naltrexone in Children. Paediatr Drugs. 2021;23(5):463-477. PMID: 34410590. https://pmc.ncbi.nlm.nih.gov/articles/PMC8475793/
8. Sankar A, Scott JG. Low-dose naltrexone for the treatment of pediatric chronic pain: a case series. Paediatr Anaesth. 2021;31(8):915-917. https://onlinelibrary.wiley.com/doi/10.1111/pan.15070